From January 13-16 2020, Novartis attended the J.P Morgan Healthcare Conference in San Francisco.
Results of the Sickle Cell World Assessment Survey (SWAY) highlight the impact this debilitating disease has on patients and their families.
Novartis shares progress in advancing its industry-leading R&D pipeline. We are uniquely positioned to deliver transformational treatments through our scale, focus on innovative medicines, diverse range of therapeutic areas and exposure to cutting-edge platforms.
We’re collaborating with AWS to build an enterprise-wide data and analytics platform to transform the way medicines are manufactured and delivered.
Novartis data at 2019 ASH and SABCS underscore our evolving R&D approach in innovative platforms to reimagine medicine and help improve patient outcomes.
New cell and gene manufacture in Stein offers hope for patients around the globe.
Novartis announced the company’s financial results for the third quarter of 2019.
European Patient Innovation Summit publishes a position paper on Digital Health from a Patient Perspective with recommendations on digital health.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.
This site is intended for a global audience.